Rua Bioscience Limited (NZSE: RUA)
Health Care · Pharmaceuticals · NZ
NZ$0.03
-2.94% today · -26.7% 1Y
Rua Bioscience Limited (NZSE: RUA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $6.60M and employs 15 people.
Over the last twelve months the share price has lost 26.7%, trading between 0.03 and 0.06.
Tweenvest scores Rua Bioscience Limited across four factors: quality 30/100, value 66/100. Its strongest factor is value.
RUA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.60M
- Revenue (TTM)
- $1.38M
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- 0.54
- 52-week high
- NZ$0.06
- 52-week low
- NZ$0.03
- Avg volume (3M)
- —
- Shares outstanding
- 339.44M
- Employees
- 15
- Next earnings
- —
About Rua Bioscience Limited
Rua Bioscience Limited, a company founded in 2016 and headquartered in Gisborne, New Zealand, is dedicated to the investigation, refinement, and production of medicinal products for both the New Zealand market and international distribution. Their offerings primarily include pharmaceuticals developed from cannabinoids. The firm officially changed its name to Rua Bioscience Limited in October 2019, having previously been known as Hikurangi Cannabis Company Limited.
- ISIN
- NZRUAE0004S1
- Founded
- 2016
- Listed since
- Oct 21, 2020
- Exchange
- New Zealand Stock Exchange
- Currency
- NZD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,189.41 | -3.59% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $270.00 | -1.15% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.10 | -2.14% |
| Roche Holding AGSWX: ROP | $371.62B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.